SCHEMBL4872170

SCHEMBL4872170

CCn1ccn(CC(=O)N2CCC(c3csc(-c4cccc(Cl)c4Cl)n3)CC2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.47
PANK3 Q9H999 1/20 0.38
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.35
CHRM5 P08912 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
HSD11B1 P28845 1/20 0.34
POLB P06746 1/20 0.34
GRIN2B Q13224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584269 0.85 GRIN2B (0.40) MAPTLMNASMN1; SMN2POLBGRIN2B
SCHEMBL3581616 0.85 MAPK1 (0.41) MAPTLMNASMN1; SMN2
SCHEMBL3576053 0.84 PIN1 (0.43) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
SCHEMBL3579063 0.83 GRIN2B (0.34) MAPTLMNASMN1; SMN2TLR7POLB
SCHEMBL3588606 0.83 CPT1A (0.44)
SCHEMBL14496017 0.82 CPT1A (0.39) ALDH1A1KDM4ETLR7
SCHEMBL3587868 0.82 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2TLR7
SCHEMBL3591786 0.81 CPT1A (0.37) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL3589486 0.80 GRIN2B (0.43) ALDH1A1HTTMEN1KMT2AKDM4E
SCHEMBL3581033 0.80 TP53 (0.36) MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962605-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS Merck & Co., Inc. (US) 2008-09-03 EP disclosed
WO-2007070433-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-06-21 WO disclosed